Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - Φάρμακα για τη θεραπεία ασθενειών των οστών - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

kyowa kirin ltd, united kingdom galabank business park, td1 1qh galashiels +44(0) 1896 664000 - burosumab - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 20mg/vial - burosumab 20mg - burosumab

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

kyowa kirin ltd, united kingdom galabank business park, td1 1qh galashiels +44(0) 1896 664000 - burosumab - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 10mg/vial - burosumab 10mg - burosumab

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

kyowa kirin ltd, united kingdom galabank business park, td1 1qh galashiels +44(0) 1896 664000 - burosumab - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 30mg/vial - burosumab 30mg - burosumab